Trial Profile
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms APTITUDE; FOREMOST
- Sponsors Amgen; Celgene Corporation
- 15 Nov 2023 Results (16-Week) assessing the effect of apremilast on the domains of the modified minimal disease activity (MDA-Joints) in early oligoarticular psoriatic arthritis patients, presented at the ACR Convergence 2023.
- 15 Nov 2023 16-Week results presented at the ACR Convergence 2023.
- 07 Nov 2023 Primary endpoint (Proportion of subjects who achieved a clinical state of minimal disease activity defined MDA-Joints)) has been met, according to an Amgen media release.